Risk Management Plans to Mitigate the Potential for Drug Shortages

On 20 May 2022 the FDA published the draft guidance on risk management plans for drug shortages. Comments may be submitted until 19 July 2022.

This guidance is intended to help stakeholders develop, maintain, and implement risk management plans (RMPs) to proactively assist in the prevention of human drug product and biological product shortages. RMPs can provide stakeholders with a framework to proactively identify, prioritize, and implement strategies to mitigate hazards that can cause a supply disruption. Such a supply disruption may lead to a drug shortage. Effective quality risk management can facilitate better, more informed decisions; can provide FDA with greater assurance that stakeholders understand and can manage the associated risks; and can potentially affect the extent and level of direct regulatory oversight.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /